Anvarbatcha Riyasdeen, Kunnathodi Faisal, Arafat Amr A, Azmi Sarfuddin, Mustafa Mohammad, Ahmad Ishtiaque, Alotaibi Haifa F
Health Research Center, Kingdom of Saudi Arabia, Ministry of Defense Health Services, Riyadh, Kingdom of Saudi Arabia.
Departments of Adult Cardiac Surgery Department, Kingdom of Saudi Arabia, Prince Sultan Cardiac Center, Riyadh, Kingdom of Saudi Arabia.
Probiotics Antimicrob Proteins. 2025 May 28. doi: 10.1007/s12602-025-10605-3.
Obesity has become a global health crisis driven by genetic, environmental, and lifestyle factors, often linked to gut microbiome imbalances. Probiotics, particularly Lactobacillus and Bifidobacterium strains, have shown promise in clinical trials by promoting weight loss, improving lipid profiles, and addressing gut dysbiosis associated with obesity. This review surveys the literature on the microbiome and obesity, emphasizing the clinical relevance of probiotics in treatment strategies. Our comprehensive PubMed search highlights the mechanisms through which probiotics influence metabolic health, including their effects on inflammation and appetite regulation. We also explore promising future research directions and the potential for integrating probiotics into clinical practice. While results are encouraging, the evidence is limited by strain variability, small sample sizes, short trial durations, and individual differences in microbiota composition. More extensive, long-term studies with standardized methods are crucial to confirm the effectiveness of probiotics as viable anti-obesity treatments.
肥胖已成为由遗传、环境和生活方式因素驱动的全球健康危机，这些因素通常与肠道微生物群失衡有关。益生菌，特别是乳酸杆菌和双歧杆菌菌株，在临床试验中已显示出有望促进体重减轻、改善血脂水平以及解决与肥胖相关的肠道生态失调问题。本综述调查了关于微生物群与肥胖的文献，强调了益生菌在治疗策略中的临床相关性。我们全面的PubMed搜索突出了益生菌影响代谢健康的机制，包括它们对炎症和食欲调节的影响。我们还探讨了有前景的未来研究方向以及将益生菌整合到临床实践中的潜力。虽然结果令人鼓舞，但证据受到菌株变异性、样本量小、试验持续时间短以及微生物群组成个体差异的限制。采用标准化方法进行更广泛、长期的研究对于确认益生菌作为可行的抗肥胖治疗方法的有效性至关重要。
